Actualización comercial
Caterpillar Inc.
€313.46
12:14 06/05/24
5 de abril de 2024
RUA Ciencias de la Vida Plc
("Ciencias de la vida de RUA", la "Empresa" o la "Grupo procesos")
Actualización comercial
RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.
Plataforma de
The first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.
Posición de efectivo
Strong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.
Desarrollo de negocios
Significant efforts have been focussed on business development activities as part of the Group's strategy to reach profitability in the short term. It has been the strategy to seek to grow the scale of contract manufacturing, and the Company is pleased to announce that it has succeeded in securing the initial development stages of a significant contract with a global enterprise. This contract represents a major milestone on the route to doubling revenues for the contract manufacturing division once fully operational. Initial development work under this contract has commenced, with an initial purchase order valued at £100,000 already received.
Additionally, as announced on 20 December 2023, the Company has successfully entered into a Material Transfer Agreement (MTA) with a global Heart Valve company. The Group's composite material has been delivered and is currently being tested by this partner. The non-calcific nature of Elast-Eon, together with the tear resistance of the novel composite (up to two times improvement over current materials), positions RUA as a leader in developing next-generation alternative leaflet material resistant to Structural Valve Degeneration (SVD). The Company is confident that these results will be of significant interest to other prospective partners and is actively exploring additional potential partnerships.
Bill Brown, Chairman of RUA Life Sciences, stated: "Trading results for FY24 represent a meaningful step in delivering on the Group's strategy outlined in November, and the efforts to focus the business on growth are showing promise."
Commenting on the Contract Manufacturing success, Bill added:
"Securing this contract underscores RUA's expertise in implantable fabrics and moves us closer to profitability. It is our first major contract since the acquisition of RUA Medical Devices in 2020 and supports our belief that there are significant market opportunities in this area."
Bill further elaborated on the heart valve composite by stating:
"Our material has exceeded expectations, demonstrating remarkable durability and energy efficiency compared to market-leading valves. We are actively seeking partnerships to leverage these compelling results. RUA believes that these outstanding results in preclinical and bench studies are a result of the unique combination of RUA's expertise in medical fabrics and the biostability of Elast-Eon"
La información comunicada en este anuncio contiene información privilegiada a los efectos del artículo 7 del Reglamento de abuso de mercado (UE) nº 596/2014.
Para más información comuníquese con:
Ciencias de la vida de RUA Bill Brown, presidente Lachlan Smith, CFO |
Tel: + 44 (0) 1294 317073 Tel: + 44 (0) 1294 317073
|
Cavendish Capital Markets Limitado (Asesor designado y Broker) Giles Balleny/Dan Hodkinson (Finanzas corporativas) Charlie Combe (corretaje) Michael Johnson (Ventas) | Tel.: +44 (0) 20 7220 0500
|
Acerca de RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Nuestra visión es mejorar la vida de millones de pacientes habilitando dispositivos médicos con Elast-EonTM, el poliuretano implantable a largo plazo líder en el mundo. Si está licenciando Elast-EonTM, la fabricación de un dispositivo o componente, o el desarrollo de dispositivos médicos de próxima generación, una empresa de RUA Life Sciences persigue nuestra visión.
La bioestabilidad de Elast-Eon™ es comparable a la de la silicona y presenta excelentes propiedades mecánicas, de contacto con la sangre y de fatiga por flexión. Estos polímeros se pueden procesar utilizando técnicas convencionales de extrusión y moldeo de termoplásticos. Con más de 8 millones de implantes y 15 años de uso clínico exitoso, los polímeros de RUA están probados en aplicaciones que permiten una vida útil a largo plazo.
Las cuatro unidades de negocio del Grupo son:
Fabricación por contrato RUA: | Desarrollador y fabricante por contrato de principio a fin de dispositivos médicos y especialista en tejidos implantables.
|
Biomateriales RUA: | Licenciante de Elast-EonTM polímeros para la industria de dispositivos médicos.
|
RUA Vascular: | Comercialización de injertos y parches vasculares quirúrgicos abiertos
|
Corazón estructural RUA: | Desarrollo de sistemas de valvas poliméricas para válvulas cardíacas. |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.